1. Home
  2. PASG

as 06-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.

Founded: 2017 Country:
United States
United States
Employees: N/A City: PHILADELPHIA
Market Cap: 76.4M IPO Year: 2020
Target Price: $9.00 AVG Volume (30 days): 243.5K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.53 EPS Growth: N/A
52 Week Low/High: $0.57 - $1.79 Next Earning Date: 08-05-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

PASG Daily Stock ML Predictions

Stock Insider Trading Activity of Passage Bio Inc. (PASG)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Borthwick Kathleen PASG SVP, INTERIM CFO Feb 10 '24 Sell $0.97 1,470 $1,425.90 28,466 SEC Form 4
Borthwick Kathleen PASG SVP, Interim CFO Dec 31 '23 Sell $0.91 10,672 $9,711.52 25,936 SEC Form 4
Cale Edgar B. PASG GC & Corporate Secretary Dec 31 '23 Sell $0.91 15,813 $14,389.83 45,995 SEC Form 4
Forman Mark S PASG Chief Medical Officer Dec 31 '23 Sell $0.91 15,813 $14,389.83 45,269 SEC Form 4
Forman Mark S PASG CHIEF MEDICAL OFFICER Aug 16 '21 Sell $0.97 1,638 $1,588.86 48,631 SEC Form 4

Share on Social Networks: